Alopecia Areata Market Synopsis

Alopecia Areata Market Size Was Valued at USD 8.24 Billion in 2023, and is Projected to Reach USD 16.06 Billion by 2032, Growing at a CAGR of 7.70% From 2024-2032.

The term Alopecia Areata Market in this report implies the global healthcare industry of products and services aimed at the diagnosis, management and treatment of alopecia areata, which is an autoimmune disorder that results in patchy hair loss in the scalp, face and other parts of the body. This market includes various advanced treatments including corticosteroids, immunosuppressants, Janus kinase inhibitors and hair growth therapies as well as ongoing research of new treatment options for alopecia areata. As prevalence continues to climb along with awareness and consistent enhancements for clinicians, the industry also encompasses diagnostic equipment, research programs, and support services geared to enhance patient experiences.

• This is definitely the case with the Alopecia Areata market particularly in view of the prevailing awareness and heightened global incidence rates of the disease as well as emerging treatment modalities which are revolutionizing the preparations’ application. Alopecia Areata an autoimmune disorder that results in hair loss on the scalp and at other place in the body at the snap of a finger affecting the lives of millions of people globally. The disorder has recently become popular because patient education increases with further understanding of the disease, and its genetic and environmental factors that heighten the immune response to the hair follicles. These advances have stimulated other treatment innovations, and existing pharma organizations investigate customized treatment therapies that cure the situation instead of concentrating on relieving the symptoms. The extenders are JAK inhibitors that have exhibit promising outcomes in clinical trials and therefore are leading a new generation of treatment for Alopecia Areata. The FDA has approved some of them, showing that there is a chance for more significant therapeutic possibilities and has stimulated key players in the market to extend even their portfolios by other new solutions.
• Similarly, thanks to active campaigns of individuals and NGOs affected by Alopecia Areata, people started talking about it, and more and more people with the illness come for the diagnosis and treatment. Due to this continuously increasing demand the Alopecia Areata treatment market has expanded with increased investment by the dermatology clinics and specialized healthcare providers for advance diagnostic facilities and technically advance treatment plans. Treatments today begin with corticosteroids and topical immunothera-peutics then advance to systemic treatments and other treatment options such as scalp hair trans-plantation, wigs and scalp micropigmentation thus offering patients more choices for the management of the medical and cosmetic aspects of the disorder. At the same time the overall market is shifting towards product specialization where products that deal with mild cases of AA and those for individuals with Alopecia Totalis or AU are developed. However, despite these progress, one of the current issues with the market is very expensive emergent treatments, and in particular, biologics and highly specialised immunotherapies, which can be unaffordable for patients with no health insurance to cover all possible contingencies. This reduces access within the L&MICs, although ongoing efforts to enhance access to and affordability of health in these regions are anticipated gradually to reduce these issues.
• Among the regional segments, North America and Europe combined occupy a much higher share of the Alopecia Areata market mainly due to improved healthcare and diagnostic indicators, and higher rates of patient awareness. These regions have large and vibrant pharmaceutical and biotechnology industries that have played very important roles in funding research and development of new therapeutic technologies. Large numbers of market participants, as well as the specific focusing of several key manufacturers involved in autoimmune diseases and dermatology, has promoted the creation of a competitive market that stimulates consistently new developments. Additionally, government funding to various autoimmune diseases, coupled with adequate reimbursement policies for innovative therapies are other factors escalating the market in these regions. All the same, the Asia Pacific region is expected to be the fastest growing market in the forecast period due to factors such as rising middle income population with enhanced health care expenditure, rising number of hospitals, and bettermed awareness of the disease. Alopecia Areata is steadily on the rise in other Asian countries such as China, India, and Japan, complemented by increased usage of sophisticated medical procedures. The region’s pharmaceutical industry is also focusing on the research of cost effective drugs in order to address a large population that is not well served. Moreover, the use of wigs, hair transplant, and newer hair regrowth solutions have become common among the consumer, and thus, driving the market in the region.
• The competition of the Alopecia Areata market is growing swiftly and various big pharmaceutical companies are giving hefty amount towards clinical trials and developing more number of products for the different stages of the disease. Major players are partnering with research organization and building gene therapy and regenerative medicines as they plan for a fix rather than temporary remedies. This focus on innovation is expected to bring more effective and long lasting therapies soon into the market. Furthermore, horizontal collaborations between pharmaceutical industries and the clinicians are enabling enhancement of early implementation of innovative treatments indicating enhancement of access to such treatments. Therefore, consisting with the notion, Alopecia Areata market will maintain its growth path due to high demands and need for enhanced medical as well as cosmetic treatments for better patients’ experience. Even if there are a lot of challenges which include, high costs of treatment, and unequal distribution of healthcare, the ever-evolving efforts to counter these vices together with the unceasing medical research portraying the future of Alopecia Areata market is one brimming with opportunities.

Alopecia Areata Market Trend Analysis

Advancements in Targeted Therapies and Personalized Medicine in the Alopecia Areata Market

• Another important market shift that has been noted in the alopecia areata industry concerns higher focus on novel treatments, particularly biologics and the JAK inhibitors. Biologics which are made from species biological produce are differ from small molecules and this differencemaker them to directly act on specific paths in the Immune system, and this make them suitable for autoimmune health problems like Alopecia areata. Among the class of JAK inhibitors, much attention has been given probably due to their implications on the cessation of signaling that triggers the immune system to attack hair follicles. Recent clinical trials have complied positive outcome with JAK inhibitors; the effectiveness of JAK inhibitors in stopping hair loss and even stimulating hair regrowth in moderate to severe alopecia areata patients. Given the continuous advancements of these therapies as well as the progressing regulatory approvals for these therapies, it is believed that the usage for this indication will grow exponentially and change the way this condition is treated. This move to these targeted therapies is a change from such broad-spectrum therapies as corticosteroids, which cause dampened immune responses and other side effects.
• First of all, the emergence of individual approach to treatment is an important factor in the development of these advanced therapies. Treatment plans are being developed that focus in the specificity of a patient’s inherited traits, the severity of the disease, and the past efficacy of certain medications. The change to a more individualised care approach not only offers better performance and outcome benefits but also decreases risk of side effects in patients. Currently, pharmaceutical companies and research organizations are devoting more resources to discovering biomarkers for diagnosing autoimmune alopecia areata and to exploring and assessing genetic tests in forming practical strategies for the illness. Consequently, this convergence of personalized medicine with biologic agents and JAK inhibitors is expected to redefine more effective, safer, and more individualized treatment strategies in the AA market.

Increased R&D, Patient Support, and Non-Invasive Treatments in the Alopecia Areata Market

• Another strong driving force that can be reported to be at work within the alopecia areata market is the boosting research and development activities that are being carried out by the key players including the pharmaceutical and biotech firms in a bid to develop newer and better treatment solutions. Since the current treatments are limited to corticosteroids and immunosuppressants, many firms are spending a lot of research money in finding new molecular targets and developing compounds. These R&D activities are directed towards the fact of studying the genetic profile and immunopathogenesis of alopecia areata so that more effective disease management therapies can be developed that have lesser side effects. Today’s biotech firms are also trying out more intricate techniques such as gene therapy, stem cell therapy and regenerative medicine which might offer permanent cure to baldness. Another sign of increased activity as well as of the huge number of new treatments expected to come to the market in the next several years is the increased activity of clinical trials including JAK inhibitors and other biologics.
• There are also trends in separate development of patient support programs and digital activities to enhance access to therapy and share more information. Such programs are aiding the patient to manage their treatment plans, get connected to the appropriate experts, and comprehend their disease type. Customers can easily have their consults and track their progress through telemedicine platforms and mobile applications especially in limited areas especially those with dermatologists or specialists. In addition, growth in the population globally is contributing to change the tendency of the market by focusing on less invasive treatment procedures. This encompasses the topical treatment options such as the use of lasers, among other minimal invasive procedures that may as well be efficient in averting extended hazards in the treatment practice. They also turn to Over the Counter (OTC) products and natural remedies which is a new trend due to the push for holistic treatment. These trends are increasing the range of treatment possibilities, and the desiring of the patient population that focuses on comfort, efficacy, and the individual approach to treatment.

Alopecia Areata Market Segment Analysis:

Alopecia Areata Market Segmented based on By Disease Type, By Cause, By Type, By Age Group and By Gender

By Disease Type, Alopecia Areata (Patchy) segment is expected to dominate the market during the forecast period

• Alopecia Areata (Patchy) is the most common form of alopecia where there are oval shaped, discrete areas of hair loss on the scalp or other parts of the body. This non-cicatricial HPV perioral dermatitis can affect people of any age and may be severe. The treatments of patchy alopecia occupies a major market share primarily by the causes and by the availability of treatment. Topical steroids, which minimize inflammation and dampen immune reactions, are widely used; immunotherapy, which seeks to change the local immune environment to grow more hair, is also part of treatment. These treatment alternatives are evidence based and gaining clinician acceptance, both of which fuel a market.
• J and growth in demand of alopecia areata (patchy) coupled with technological improvements in treatment procedures continues to drive the market forward. It means people themselves choose treatments and are eager to get the most efficient ones, which creates a constant flow of demand for new approaches. Hence, the market for managing the condition is continuously and dynamically growing and is dominated by pharmaceutical companies and research institutions. Besides, growing incidences of awareness campaigns and education regarding the effective therapies along with social acceptance and less taboos regarding the diseases are contributing to the growth and dominance of the market in the overall alopecia treatment markets.

By Gender, Female segment held the largest share of in 2023

• Female alopecia comprises a group of diseases and varieties different from those typical of male patients; hormonal shifts, pregnancy modifications, stress, and the presence of any diseases are potential triggers. This market is currently the largest segment within the alopecia market since hair loss is both polymorphic and acquired for various reasons in women. Treatment for female baldness include systemic: contraceptives and anti-androgens since alopecia may be as a result of hormonal changes. Also, minoxidil treatment is designed for women applies topically and promotes hair growth and thinning. This has led to very specific condition treatments as well as higher levels of care formulations that are specific to women’s hair needs.
• In addition to the medical treatments, the market offers a rather broad number of cosmetics meant to address the issue of female hair loss. Such products include volumizing shampoos, conditioners as well as fibers that are used to help improve the look of thinning hair. Such factors as awareness of the female hair health problems coupled by the increased visibility of women’s baldness in media and discussions has significantly stimulated demand for such products. Since cultural perceptions change and more woman actively look for a solution as to how they can solve this problem, the demand for female baldness solutions only grows, both in terms of medical procedures and aesthetic ones. These specific treatments make the targeting of consumer needs and effective cure paths as the key reason for the female alopecia market being the largest segment.

Alopecia Areata Market Regional Insights:

North American is Expected to Dominate the Market Over the Forecast period

• North American alopecia areata market is dominating the global market majorly due to improved healthcare infrastructure and awareness among the people of United States and Canada. In the United States, market development is shifting because of a well-developed dermatological network and substantial health insurance coverage. The united state has a good number of patent suffering from alopecia areata, this market enjoys good diagnose and treatment rates. That is why autoimmune disorders and the adoption of new methods in the existing management of diseases are among the factors that have largely contributed to the growth of the market. In addition, many research institutions and bio-tech companies have been investing in alopecia areata because of the wide scope of alopecia areata; thus propelling the market growth to increase at an incredible high rate.
• As the country with a developed healthcare system and gradually rising HC spending, Canada is yet another important market for the North American alopecia areata treatment industry. The emphasis of most Canadian healthcare on accessibility and patient-centered approach mean that a large number of a population with alopecia areata can receive adequate, quick, and effective treatment. This market is growing because more Canadians are developing autoimmune diseases and more healthcare services are offered to them. Clinical research is still ongoing in Canada, so new therapies are being discovered; this demonstrates the country’s interest in improving the treatment of alopecia areata. Jointly, high disease prevalence in North America, coupled with the constantly improving medical facilities and research on the disease, have made North America to dominate the global alopecia areata market.

Active Key Players in the Alopecia Areata Market

• Pfizer Inc
• Dr. Reddy's Laboratories Ltd
• Lilly
• Sun Pharmaceutical Industries Ltd
• GSK plc
• Johnson & Johnson Consumer Inc
• Lupin
• Croma-Pharma GmbH
• Viviscal Limited (A Subsidiary of Church & Dwight Co.)
• AdvaCare Pharma
• Wellona Pharma
• Teva Pharmaceuticals USA Inc
• Croma-Pharma GmbH
• Follicum AB
• Nanogen
• Vitabiotics Ltd
• Reistone Biopharma
• TechnoDerma Medicines Inc and Other Key Players

Key Industry Developments in the Alopecia Areata Market

• Today Lilly has revealed that, through NOC approval for OLUMIANT, which occurred in January 2024, baricitinib has now been registered by Health Canada for severe alopecia areata treatment. OLUMIANT is administered once daily, in its systemic therapy for individuals with severe AA, being available in tablet dosages of 2 mg or 4 mg. In patients who have severe alopecia areata, the dose of OLUMIANT prescribed is 2 mg/day; the dose may be increased to 4 mg/day if the condition is no iamproving. Thus, a patient with basically near total or complete hair loss on the scalp, with or without significantlosses of eyelashes and/or eyebrows, may be started at a 4 mg/day oral dose. However, if an adequate response is obtained on 4 mg/day, dose reduction may be attempted by using 2 mg/day. While Onostatin, in contrast to L-asparaginase, does not require strict special precautions, its use is contraindicated in combination with other JAK inhibitors, biologic immunomodulators, azathioprine, cyclosporine and other potent immunosuppressant
• Pfizer Inc. declared the acquisition process of Seagen Inc. successful in December 2023, which is a global biotechnology company, engaged in the discovery, research, development, and providing novel cancer treatments. Pfizer bought all the remaining common shares of Seagen at USD 229 per share in cash, which means about USD 43 billion of enterprise value.
• In the same month in 2023, it will be realised that the FDA has granted its approval to Pfizer Inc to market LITFULO (ritlecitinib) a once daily oral therapy for arthritis prone individuals of 12 years and above by the company. Subsequently, the dose of LITFULO that has been recommended and approved is 50 mg. This approval puts LITFULO as the only treatment with FDA approval for adolescents (12+) with severe alopecia areata.
• , Sun Pharmaceutical Industries Limited (along with subsidiaries and/ or affiliated companies – “Sun Pharma”) and Concert Pharmaceuticals, Inc. ( “Concert” ) are pleased to announce that they have entered into a definite business combination under which Sun Pharma shall purchase all the issued and outstanding shares of Concert through an offer for USD 8.00 per share of common stock in cash, or at a value of USD 576 million in equity.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Alopecia Areata Market by Disease Type
 4.1 Alopecia Areata Market Snapshot and Growth Engine
 4.2 Alopecia Areata Market Overview
 4.3 Alopecia Areata (Patchy)
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Alopecia Areata (Patchy): Geographic Segmentation Analysis
 4.4 Alopecia Areata Totalis
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Alopecia Areata Totalis: Geographic Segmentation Analysis
 4.5 Alopecia Areata Universalis
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Alopecia Areata Universalis: Geographic Segmentation Analysis
 4.6 Others
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Others: Geographic Segmentation Analysis

Chapter 5: Alopecia Areata Market by Cause
 5.1 Alopecia Areata Market Snapshot and Growth Engine
 5.2 Alopecia Areata Market Overview
 5.3 Non-Genetic
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Non-Genetic: Geographic Segmentation Analysis
 5.4 Genetic
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Genetic: Geographic Segmentation Analysis

Chapter 6: Alopecia Areata Market by Type
 6.1 Alopecia Areata Market Snapshot and Growth Engine
 6.2 Alopecia Areata Market Overview
 6.3 Treatment
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Treatment: Geographic Segmentation Analysis
 6.4 Diagnosis
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Diagnosis: Geographic Segmentation Analysis

Chapter 7: Alopecia Areata Market by Age Group
 7.1 Alopecia Areata Market Snapshot and Growth Engine
 7.2 Alopecia Areata Market Overview
 7.3 Below 18 Years
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Below 18 Years: Geographic Segmentation Analysis
 7.4 18-50 Years
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 18-50 Years : Geographic Segmentation Analysis
 7.5 Above 50 Years
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Above 50 Years: Geographic Segmentation Analysis

Chapter 8: Alopecia Areata Market by Gender
 8.1 Alopecia Areata Market Snapshot and Growth Engine
 8.2 Alopecia Areata Market Overview
 8.3 Female
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Female: Geographic Segmentation Analysis
 8.4 Male
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Male: Geographic Segmentation Analysis

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Benchmarking
  9.1.2 Alopecia Areata Market Share by Manufacturer (2023)
  9.1.3 Industry BCG Matrix
  9.1.4 Heat Map Analysis
  9.1.5 Mergers and Acquisitions
  
 9.2 PFIZER INC
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Role of the Company in the Market
  9.2.5 Sustainability and Social Responsibility
  9.2.6 Operating Business Segments
  9.2.7 Product Portfolio
  9.2.8 Business Performance
  9.2.9 Key Strategic Moves and Recent Developments
  9.2.10 SWOT Analysis
 9.3 DR. REDDY'S LABORATORIES LTD
 9.4 LILLY
 9.5 SUN PHARMACEUTICAL INDUSTRIES LTD
 9.6 GSK PLC
 9.7 JOHNSON & JOHNSON CONSUMER INC
 9.8 LUPIN
 9.9 CROMA-PHARMA GMBH
 9.10 VIVISCAL LIMITED (A SUBSIDIARY OF CHURCH & DWIGHT CO.)
 9.11 ADVACARE PHARMA
 9.12 WELLONA PHARMA
 9.13 TEVA PHARMACEUTICALS USA INC
 9.14 CROMA-PHARMA GMBH
 9.15 FOLLICUM AB
 9.16 NANOGEN
 9.17 VITABIOTICS LTD
 9.18 REISTONE BIOPHARMA
 9.19 TECHNODERMA MEDICINES INC
 9.20 OTHER ACTIVE PLAYERS

Chapter 10: Global Alopecia Areata Market By Region
 10.1 Overview
 10.2. North America Alopecia Areata Market
  10.2.1 Key Market Trends, Growth Factors and Opportunities
  10.2.2 Top Key Companies
  10.2.3 Historic and Forecasted Market Size by Segments
  10.2.4 Historic and Forecasted Market Size By Disease Type
  10.2.4.1 Alopecia Areata (Patchy)
  10.2.4.2 Alopecia Areata Totalis
  10.2.4.3 Alopecia Areata Universalis
  10.2.4.4 Others
  10.2.5 Historic and Forecasted Market Size By Cause
  10.2.5.1 Non-Genetic
  10.2.5.2 Genetic
  10.2.6 Historic and Forecasted Market Size By Type
  10.2.6.1 Treatment
  10.2.6.2 Diagnosis
  10.2.7 Historic and Forecasted Market Size By Age Group
  10.2.7.1 Below 18 Years
  10.2.7.2 18-50 Years
  10.2.7.3 Above 50 Years
  10.2.8 Historic and Forecasted Market Size By Gender
  10.2.8.1 Female
  10.2.8.2 Male
  10.2.9 Historic and Forecast Market Size by Country
  10.2.9.1 US
  10.2.9.2 Canada
  10.2.9.3 Mexico
 10.3. Eastern Europe Alopecia Areata Market
  10.3.1 Key Market Trends, Growth Factors and Opportunities
  10.3.2 Top Key Companies
  10.3.3 Historic and Forecasted Market Size by Segments
  10.3.4 Historic and Forecasted Market Size By Disease Type
  10.3.4.1 Alopecia Areata (Patchy)
  10.3.4.2 Alopecia Areata Totalis
  10.3.4.3 Alopecia Areata Universalis
  10.3.4.4 Others
  10.3.5 Historic and Forecasted Market Size By Cause
  10.3.5.1 Non-Genetic
  10.3.5.2 Genetic
  10.3.6 Historic and Forecasted Market Size By Type
  10.3.6.1 Treatment
  10.3.6.2 Diagnosis
  10.3.7 Historic and Forecasted Market Size By Age Group
  10.3.7.1 Below 18 Years
  10.3.7.2 18-50 Years
  10.3.7.3 Above 50 Years
  10.3.8 Historic and Forecasted Market Size By Gender
  10.3.8.1 Female
  10.3.8.2 Male
  10.3.9 Historic and Forecast Market Size by Country
  10.3.9.1 Bulgaria
  10.3.9.2 The Czech Republic
  10.3.9.3 Hungary
  10.3.9.4 Poland
  10.3.9.5 Romania
  10.3.9.6 Rest of Eastern Europe
 10.4. Western Europe Alopecia Areata Market
  10.4.1 Key Market Trends, Growth Factors and Opportunities
  10.4.2 Top Key Companies
  10.4.3 Historic and Forecasted Market Size by Segments
  10.4.4 Historic and Forecasted Market Size By Disease Type
  10.4.4.1 Alopecia Areata (Patchy)
  10.4.4.2 Alopecia Areata Totalis
  10.4.4.3 Alopecia Areata Universalis
  10.4.4.4 Others
  10.4.5 Historic and Forecasted Market Size By Cause
  10.4.5.1 Non-Genetic
  10.4.5.2 Genetic
  10.4.6 Historic and Forecasted Market Size By Type
  10.4.6.1 Treatment
  10.4.6.2 Diagnosis
  10.4.7 Historic and Forecasted Market Size By Age Group
  10.4.7.1 Below 18 Years
  10.4.7.2 18-50 Years
  10.4.7.3 Above 50 Years
  10.4.8 Historic and Forecasted Market Size By Gender
  10.4.8.1 Female
  10.4.8.2 Male
  10.4.9 Historic and Forecast Market Size by Country
  10.4.9.1 Germany
  10.4.9.2 UK
  10.4.9.3 France
  10.4.9.4 Netherlands
  10.4.9.5 Italy
  10.4.9.6 Russia
  10.4.9.7 Spain
  10.4.9.8 Rest of Western Europe
 10.5. Asia Pacific Alopecia Areata Market
  10.5.1 Key Market Trends, Growth Factors and Opportunities
  10.5.2 Top Key Companies
  10.5.3 Historic and Forecasted Market Size by Segments
  10.5.4 Historic and Forecasted Market Size By Disease Type
  10.5.4.1 Alopecia Areata (Patchy)
  10.5.4.2 Alopecia Areata Totalis
  10.5.4.3 Alopecia Areata Universalis
  10.5.4.4 Others
  10.5.5 Historic and Forecasted Market Size By Cause
  10.5.5.1 Non-Genetic
  10.5.5.2 Genetic
  10.5.6 Historic and Forecasted Market Size By Type
  10.5.6.1 Treatment
  10.5.6.2 Diagnosis
  10.5.7 Historic and Forecasted Market Size By Age Group
  10.5.7.1 Below 18 Years
  10.5.7.2 18-50 Years
  10.5.7.3 Above 50 Years
  10.5.8 Historic and Forecasted Market Size By Gender
  10.5.8.1 Female
  10.5.8.2 Male
  10.5.9 Historic and Forecast Market Size by Country
  10.5.9.1 China
  10.5.9.2 India
  10.5.9.3 Japan
  10.5.9.4 South Korea
  10.5.9.5 Malaysia
  10.5.9.6 Thailand
  10.5.9.7 Vietnam
  10.5.9.8 The Philippines
  10.5.9.9 Australia
  10.5.9.10 New Zealand
  10.5.9.11 Rest of APAC
 10.6. Middle East & Africa Alopecia Areata Market
  10.6.1 Key Market Trends, Growth Factors and Opportunities
  10.6.2 Top Key Companies
  10.6.3 Historic and Forecasted Market Size by Segments
  10.6.4 Historic and Forecasted Market Size By Disease Type
  10.6.4.1 Alopecia Areata (Patchy)
  10.6.4.2 Alopecia Areata Totalis
  10.6.4.3 Alopecia Areata Universalis
  10.6.4.4 Others
  10.6.5 Historic and Forecasted Market Size By Cause
  10.6.5.1 Non-Genetic
  10.6.5.2 Genetic
  10.6.6 Historic and Forecasted Market Size By Type
  10.6.6.1 Treatment
  10.6.6.2 Diagnosis
  10.6.7 Historic and Forecasted Market Size By Age Group
  10.6.7.1 Below 18 Years
  10.6.7.2 18-50 Years
  10.6.7.3 Above 50 Years
  10.6.8 Historic and Forecasted Market Size By Gender
  10.6.8.1 Female
  10.6.8.2 Male
  10.6.9 Historic and Forecast Market Size by Country
  10.6.9.1 Turkey
  10.6.9.2 Bahrain
  10.6.9.3 Kuwait
  10.6.9.4 Saudi Arabia
  10.6.9.5 Qatar
  10.6.9.6 UAE
  10.6.9.7 Israel
  10.6.9.8 South Africa
 10.7. South America Alopecia Areata Market
  10.7.1 Key Market Trends, Growth Factors and Opportunities
  10.7.2 Top Key Companies
  10.7.3 Historic and Forecasted Market Size by Segments
  10.7.4 Historic and Forecasted Market Size By Disease Type
  10.7.4.1 Alopecia Areata (Patchy)
  10.7.4.2 Alopecia Areata Totalis
  10.7.4.3 Alopecia Areata Universalis
  10.7.4.4 Others
  10.7.5 Historic and Forecasted Market Size By Cause
  10.7.5.1 Non-Genetic
  10.7.5.2 Genetic
  10.7.6 Historic and Forecasted Market Size By Type
  10.7.6.1 Treatment
  10.7.6.2 Diagnosis
  10.7.7 Historic and Forecasted Market Size By Age Group
  10.7.7.1 Below 18 Years
  10.7.7.2 18-50 Years
  10.7.7.3 Above 50 Years
  10.7.8 Historic and Forecasted Market Size By Gender
  10.7.8.1 Female
  10.7.8.2 Male
  10.7.9 Historic and Forecast Market Size by Country
  10.7.9.1 Brazil
  10.7.9.2 Argentina
  10.7.9.3 Rest of SA

Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies

Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research